

## Clinical Guideline:

**Authors: Dr Katherine McDevitt, Dr Jenna Harris, Judith Soko**

**For use in:** EoE Neonatal Units  
Guidance specific to the care of neonatal patients.

**Used by: EoE Neonatal Units**

**Key Words: Exchange Transfusion, Jaundice, Neonatal Jaundice**

**Date of Ratification: June 2022**

**Review due: June 2025**

**Registration No: NEO-ODN-2022-9**

**Approved by:**

Neonatal Clinical Oversight Group	
Clinical Lead Matthew James	<b>Matthew James</b>

Insert Title of Procedural Document Version							
<b>Document Type:</b>		Guideline					
<b>Central Index Number:</b>		The number of the document on the Document Library. Leave blank if new					
<b>Document Owner: (Name, job title and email)</b>							
<b>Division:</b>		Family and Integrated Support Services Division					
<b>Directorate/CBU:</b>		FISS - Family Services CBU - Neonates (NICU & SCBU)					
<b>Scope:</b>		Trust-wide					
<b>Standards and Legislation and key related documents:</b>		State any standards, legislation or key related documents that are relevant and current. If you have a SOP, please state the overarching policy name here.					
<b>First-Level Approval: (Specialty)</b>		Select			<b>Date:</b>	Enter date	
<b>First-Level Approval: (CBU)</b>		Select			<b>Date:</b>	Enter date	
<b>First-Level Approval: (Divisional Leadership Board)</b>		Select			<b>Date:</b>	Enter date	
<b>First-Level Approval: NMAG</b>		<b>First-Level Approval: D&amp;TC</b>		<b>First-Level Approval: TIPCC</b>		<b>First-Level Approval: Safeguarding Committee</b>	
<i>Tick</i> <input type="checkbox"/>	Enter date	<i>Tick</i> <input type="checkbox"/>	Enter date	<i>Tick</i> <input type="checkbox"/>	Enter date	<i>Tick</i> <input type="checkbox"/>	Enter date
<b>Review Date:</b>		Enter date					
<b>Second-Level Approval: (if required)</b>		Select.			<b>Date:</b>	Enter date	
<b>Target Audience:</b>		Choose an item.					
<b>Staff Side Approval:</b>		Select.			<b>Date:</b>	Enter date	
<b>CAUTION: REFER TO THE DOCUMENT LIBRARY FOR THE MOST RECENT VERSION OF THIS DOCUMENT</b> <b>UNCONTROLLED COPY WHEN PRINTED</b>							

## VERSION CONTROL SUMMARY

Version:	Page or section:	Description of change:	Date approved:	Date published:

## CONTENTS

VERSION CONTROL SUMMARY .....	3
1. INTRODUCTION .....	5
2. PURPOSE .....	5
3. SCOPE .....	5
4. INDICATIONS .....	5
5. PRENATAL MANAGEMENT .....	6
6. PREPARATION .....	6
7. THE PROCEDURE .....	9
8. MONITORING & COMPLICATIONS .....	10
9. REFERENCES .....	12
APPENDIX A: EQUIPMENT AND SET-UP .....	13
APPENDIX B: SUMMARY FLOW CHART .....	15
APPENDIX C: NEONATAL EXCHANGE TRANSFUSION RECORD .....	16
APPENDIX D: QUALITY ASSURANCE CHECKLIST .....	18
NOTES FOR AUTHORS .....	20

**The latest version of this document is on The Document Library.**

**Any printed copies must be checked against the Document Library version to ensure that the latest version is being used.**

## Exchange Transfusion in Neonates

### 1. INTRODUCTION

- 1.1 Jaundice is common in the first few days of life, but significant hyperbilirubinaemia is associated with risks of brain damage, kernicterus and long-term disability. It is usually successfully managed with phototherapy and feeding support.
- 1.2 Exchange transfusion may be indicated in significant hyperbilirubinaemia secondary to acute haemolysis, by removing the affected red blood cells and circulating maternal antibodies to reduce red cell destruction. This involves the removal of patient blood in aliquots and replacement with donor blood.

### 2. PURPOSE

- 2.1 To help staff manage significant hyperbilirubinaemia safely and prevent complications of brain damage and kernicterus.

### 3. SCOPE

- 3.1 All health-care professionals (permanent and temporary) working on NICU/SCBU within East of England Neonatal ODN

### 4. INDICATIONS

- 4.1 Measured serum bilirubin is on or above exchange transfusion line (<https://www.nice.org.uk/guidance/cg98/resources>) and not responding to intensive phototherapy
- 4.2 Risk factors that increase the risk of kernicterus:
  - Rate of rise of bilirubin >8.5micromol/litre/hour
  - Clinical features of acute bilirubin encephalopathy
  - Evidence of acute haemolysis
  - Acute anaemia at birth (Hb <100g/l)
  - Cord bilirubin >80micromol/litre

## 5. PRENATAL MANAGEMENT

- 5.1 The need for exchange transfusion may be predicted antenatally, particularly if atypical antibodies are detected or there is known rhesus disease. In this instance, it is helpful to organise blood in advance, as it may be difficult to source for rare maternal antibodies.
- 5.2 These patients should be highlighted during the perinatal meeting and a joint plan made for each patient.

## 6. PREPARATION

- 6.1 Total serum bilirubin above exchange transfusion threshold is a medical emergency and it is essential that the consultant on-call is informed. The infant should be admitted to NICU/SBCU for the procedure.
- 6.2 Start intensive phototherapy and IV fluids (at one day ahead) as soon as possible. Consider the use of 360 phototherapy if available.
- 6.3 Consider the administration of IVIG.

Use should be considered when managing a baby with haemolytic disease of the newborn if there is delay in commencing an exchange transfusion due to the availability of blood. It can also be used as an adjunct to phototherapy to try and reduce the need for exchange transfusion.

Use IVIG 500mg/kg over 4 hours.

Parents and carers should be offered information on the following:

- Why IVIG is being considered
- Why IVIG may be needed to treat significant hyperbilirubinemia
- The possible adverse effects of IVIG
- When it will be possible for parents/carers to see the baby

The adverse effects are fever, allergic reaction (including anaphylaxis), hypoglycaemia, hypotension and fluid overload.

6.4 Inform parents of the procedure, gain consent and document the conversation.

Parents should be made aware of the following:

- The need to admit the baby to NICU/SCBU
- Why an exchange transfusion is being considered and how it will treat significant hyperbilirubinaemia
- The duration of the procedure
- The risks of the procedure
- When it will be possible for parents to see the baby

The risks are air embolus, thrombosis, haemorrhage, hypotension, IVH (preterm infants), electrolyte derangement, arrhythmias, dilutional coagulopathy, necrotising enterocolitis, sepsis, hypothermia.

There is a 3 in 1000 risk of death.

Follow the trust policy if parents refuse to give consent for the transfusion. A child should be given such treatment as is immediately necessary for the preservation of life or prevention of serious harm or deterioration.

6.5 Calculate the required transfusion volume and contact Blood Bank to order the blood (CMV negative, irradiated, less than 5 days old). A group and save sample from the infant and mother will be required to cross-match blood.

Unless otherwise indicated, a **double-volume exchange of 170ml/kg** should be used.

6.6 A minimum of 3 staff are required for the procedure. A 1:1 nurse and doctor will be required throughout the procedure (2-3 hours), plus one other healthcare professional. Staff should be bleep-free. Consider delegation and reallocation of the workload.

6.7 Gather your equipment – please see section 7.1

Ensure appropriate continuous monitoring in place – including ECG, temperature probe, blood pressure and oxygen saturation monitoring.

Document baseline observations on the Neonatal Exchange Blood Transfusion Record

6.8 Keep the infant nil by mouth throughout the procedure

6.9 Obtain access – you will need either:

- UAC and UVC (optimum)
- Peripheral cannula and UAC
- Peripheral cannula and 2 x peripheral arterial line
- UVC only

- **Note: arterial lines should only be used for the withdrawal of blood, NOT the infusion of donor blood**

6.10 Baseline bloods (including group and save, full blood count, clotting, urea & electrolytes, bone profile and split bilirubin), blood glucose and blood gas should be taken prior to the procedure.

Obtain a pre-transfusion blood spot for neonatal screening and consider the need to take diagnostic samples for storage.

6.11 **Phototherapy should continue throughout the procedure.**

6.12 Determine the transfusion rate and total transfusion time. You will be taking aliquots of a set size over 5-minute intervals. (Aliquot = volume of blood to be removed)

WEIGHT	ALIQUOT SIZE	INFUSION SPEED
<1500g	5ml	1ml/min (60ml/hr)
1500g-2499g	10ml	2ml/min (120ml/hr)
2500g-3499g	15ml	3ml/min (180ml/hr)
>3500g	20ml	4ml/min (240ml/hr)

Divide your calculated total required volume (170ml x birth weight) by your ml/min to obtain total transfusion time.

*Example: For a 3.5kg term infant undergoing double volume exchange transfusion.*

*3.5 x 170 = 595ml (TOTAL REQUIRED VOLUME)*

*595ml divided by 4ml/min = 148.75 minutes (TOTAL TRANSFUSION TIME)*

*595ml divided by 20ml aliquots = 29.75 separate aliquots*

6.13 Please see Appendix 2 for reference flow chart

6.14 During an exchange transfusion DO NOT:

- Stop continuous phototherapy
- Perform a single volume exchange
- Use albumin priming
- Routinely administer IV calcium



## 7. THE PROCEDURE

### 7.1 Equipment required:

- Appropriate means of thermoregulation for the infant
- Observation monitoring equipment, including ECG, temperature probe, blood pressure and oxygen saturation monitoring
- Blood sugar monitoring
- Sterile plastic sheet to place under sterile drape
- IV infusion pump (Allaris Signature)
- 10% dextrose
- Selection of disposable sterile Luer lock syringes and needles
- 3-way tap x 2
- Chlorhexidine
- Red cell infusion set with appropriate filters
- Blood warmer (if infusion is given continuously, not suitable for “push-pull” method)
- Drainage bag and extension sets
- Urine bag or cotton balls to monitor urine output
- Oral sucrose/pacifier
- Personal protective equipment for sterile procedure
- Sharps bin
- Blood bottles, including clotting (green), EDTA (red) , serum gel (brown) and fluoride (yellow) - as per section 6.10 and 8.4
- Neonatal resuscitation equipment
- Timing device for infusion and withdrawal of aliquots

7.2 Ensure that equipment is set-up using aseptic technique and all lines are primed appropriately. Albumin priming is not recommended.

### 7.3 Infusion of donor red cells at a constant rate, with simultaneous withdrawal of aliquots of blood from the infant

Donor blood is infused at a constant rate through a venous line – see section 6.12 for calculation of infusion rate.

Simultaneously, aliquots of blood are withdrawn from the infant through an arterial line over 5 minutes – as calculated in section 6.12.

*Safety Point:* The volume limit should be set on the pump for each quantity of blood being given. This limit should only be increased after verbal confirmation between nurses and doctor that the corresponding aliquot volume has been successfully removed.

If the procedure is halted for any reason or the arterial line stops sampling, it is **essential** that the infusion of donor blood is stopped immediately to prevent hypervolaemia.

Please see diagram in Appendix 1.

#### 7.4 One person push-pull technique via single vascular access

The UVC is connected to the red cell giving set via 2 separate 3-way taps (to ensure a closed system). On the 3-way tap nearest the infant, a 50ml syringe is attached. On the 3-way tap furthest from the infant, a drainage bag is attached.

Standard cycle over 5 minutes:

- A aliquot of blood is withdrawn from the infant (as calculated in section 6.12)
- The 3 way tap is turned off to the infant, and on to the waste
- Blood is pushed into the waste bag
- The 3-way tap is turned off to the waste, and on to the donor blood
- The same size aliquot of blood is withdrawn from the bag
- The 3-way tap is turned off the donor blood, and on to the infant
- The aliquot of blood is delivered to the infant

The procedure always starts with the withdrawal of blood to ensure the infant's circulation is not overloaded.

Please see diagram in Appendix 1.

## 8. MONITORING & COMPLICATIONS

### 8.1 During the procedure:

- Continuous monitoring of HR and rhythm, oxygen saturations, respiratory rate and temperature. Note: any deviation from baseline may indicate an adverse reaction.
- A staff member should be responsible for accurate recording of blood input and withdrawal, and record observations with each cycle of the procedure.
- Blood gas and blood glucose (including ionised calcium, potassium and lactate) should be measured half hourly during the procedure.
- Bloods, including full blood count, clotting, urea & electrolytes, bone profile and split bilirubin, should be taken halfway through the procedure.

### 8.2 Closely observe the infant, watching for cyanosis, distress, pallor, vomiting or abdominal distension

### 8.3 Complications

Cardiac arrest – Consider air embolism, cold blood, hypovolaemia or hypo/hyperkalaemia. Manage according to NLS algorithm and correct above issues if present.

Convulsions – Stop exchange transfusion. Manage seizure. Check pH, glucose, calcium and magnesium.

Hypothermia – Confirm placement of temperature probe. Confirm blood warmer is at 37c. Slow the exchange.

Hyperglycaemia – Donor blood is preserved in dextrose. Blood glucose levels can be elevated during the procedure and generally resolve without intervention.

Hypoglycaemia – May occur during, or shortly after, the exchange. Follow local hypoglycaemia guidelines. Repeat blood glucose within 15 minutes and continue to monitor closely.

Hyperkalaemia – Lower risk with red cells less than 5 days old. Stop exchange if potassium >7.0. Peaked T waves, wide QRS or ventricular ectopics may be seen on ECG monitoring. Manage as per local hyperkalaemia guidelines. The exchange can be restarted if potassium is <6.0.

Hypocalcaemia – Rare with new preservative anticoagulants. If ionised calcium <0.8, then flush catheter dead space with normal saline and give urgent IV correction (1-2ml/kg calcium gluconate 10% via central line over 10 minutes). Prolonged QT may be seen on ECG monitoring.

Metabolic Acidosis – Mild metabolic acidosis is common and may not require treatment. If base excess drops below -10, then flush catheter dead space with normal saline and give a half bicarbonate correction ( $[\text{body weight} \times \text{base excess} \times 0.3]/2 = \text{mmol of sodium bicarbonate } 4.2\%$ ). If acidosis persists or worsens, consider stopped exchange.

Thrombocytopenia – Donor blood is platelet depleted, so the platelet count will tend to fall. This rarely needs intervention. If platelets are <50, consider stopping exchange and arranging platelet transfusion via a peripheral line.

Air Embolus – Preventable by careful set-up and priming of lines. Observe lines for presence of air during the exchange and ensure 3-way taps are closed with filling or expelling contents of the syringe.

Anaemia/Polycythaemia – Gently agitate donor blood at frequent intervals to prevent separation of red cells and plasma.

#### 8.4 After the procedure:

- Measure the serum split bilirubin, electrolytes, bone profile, full blood count and clotting profile within 2 hours

- Monitor blood glucose hourly for 4 hours, and closely thereafter
- Keep nil by mouth for 24 hours after the procedure
- Continue intensive phototherapy initially, and then manage according to bilirubin result and NICE treatment threshold graphs
- Maintain central access until confident that no further exchanges are required


8.5 The infant should receive irradiated blood for any transfusions 6 months post-exchange to eliminate the risk of graft vs host disease

## 9. REFERENCES


- 9.1
- National Institute for Health Care and Excellence *Jaundice in newborn babies under 28 days* June 2020
  - Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee *Handbook of Transfusion Medicine* 5<sup>th</sup> Edition, January 2014

## APPENDIX A: EQUIPMENT AND SET-UP

Infusion of donor red cells at a constant rate, with simultaneous withdrawal of aliquots of blood from the infant



One person push-pull technique via single vascular access



## APPENDIX B: SUMMARY FLOW CHART

Please add any appendices relevant to this document as required. Once added please update the auto-contents by selecting the auto-contents table, followed by **Update Table** and finally **Update entire table**.

**TO INSERT PDF**

## APPENDIX C: NEONATAL EXCHANGE TRANSFUSION RECORD

Name			
Date of Birth			
DIS Number			
Gestation		Total Volume of Transfusion (ml/kg)	
Blood Group		Total Required Volume (ml)	
DAT		Aliquot Size / Infusion Speed	
Mothers Name		Aliquot Frequency	
Mothers DIS Number		Time for Transfusion (min)	

Aliquot Number	Time	IN		OUT		Total Balance (In-Out)	Blood Taken?	HR	RR	Temp	BP	SpO2
		Aliquot ml	Total ml	Aliquot ml	Total ml							
Pre		-	-	-	-	-	-					
1												
2												
3												
4												
5												
6												
7												
8												
9												
10												
11												
12												
13												
14												
15												
16												
17												
18												
19												
20												
21												
22												
23												
24												
25												
26												
27												
28												





29												
30												

## APPENDIX D: QUALITY ASSURANCE CHECKLIST

### COMPLIANCE OFFICER'S USE ONLY

		Y/N/ n/a	COMMENTS (to author for amendments)
1	<b>Title of document</b>		
	Is the title clear and unambiguous		
2	<b>Type of document (e.g. procedure, guidance)</b>		
	Is it clear whether the document is a procedure, guideline, standard operating procedure?		
3	<b>Introduction</b>		
	Are reasons for the development of the document clearly stated?		
4	<b>Content</b>		
	Is the standard model template used?		
	Is the document in the correct format? <a href="#">Please refer to Trust-Wide Writing Style Guide</a>		
	<ul style="list-style-type: none"><li>Paragraphs numbered consecutively</li></ul>		
	<ul style="list-style-type: none"><li>Headers: only on front page to contain logo</li></ul>		
	<ul style="list-style-type: none"><li>Footers: on every page except front page</li></ul>		
	Are the Version Control numbers correct in the panel and the footer		
	Are the objectives/aims clearly stated?		
	Does this document concern the handling, moving or storage of personal identifiable or commercially sensitive information? If yes, has a Summary Privacy Impact Assessment been completed?		
5	<b>Evidence Base</b>		
	Is the type of evidence to support the document explicitly identified?		
	Are associated documents referenced?		
6	<b>Approval Route</b>		
	Does the document identify which committee/group will approve it?		
7	<b>Review Date</b>		
	Is the review date identified?		

**If answers to any of the above questions is 'no', then this document is not ready for approval, it needs further review.**

### COMPLIANCE TEAM:

1.	Date Comments returned to author by Compliance Lead	
2.	Date of Compliance Team approval	
3.	Name of Compliance Lead	

**FIRST-LEVEL APPROVAL: Enter name of Specialty meeting/group**

If the committee/group is happy to approve this document would the chair please sign below and send the document and the minutes from the approval committee to the author. To aid distribution all documentation should be sent electronically wherever possible.

<b>Name</b>		<b>Date</b>	Enter date
<b>Signature</b>			

**FIRST-LEVEL APPROVAL: Enter name of CBU meeting**

If the committee/group is happy to approve this document would the chair please sign below and send the document and the minutes from the approval committee to the author. To aid distribution all documentation should be sent electronically wherever possible.

<b>Name</b>		<b>Date</b>	Enter date
<b>Signature</b>			

**FIRST-LEVEL APPROVAL: Enter name of Divisional Leadership Board**

If the committee/group is happy to approve this document would the chair please sign below and send the document and the minutes from the approval committee to the author. To aid distribution all documentation should be sent electronically wherever possible.

<b>Name</b>		<b>Date</b>	Enter date
<b>Signature</b>			

**FIRST-LEVEL APPROVAL: Complete all that apply**

If the committee/group is happy to approve this document would the chair please sign below and send the document and the minutes from the approval committee to the author. To aid distribution all documentation should be sent electronically wherever possible.

<b>NMAG</b>		<b>D&amp;TC</b>	
<b>Name</b>		<b>Name</b>	
<b>Date</b>	Enter date	<b>Date</b>	Enter date
<b>Signature</b>		<b>Signature</b>	
<b>TIPCC</b>		<b>Safeguarding</b>	
<b>Name</b>		<b>Name</b>	
<b>Date</b>	Enter date	<b>Date</b>	Enter date
<b>Signature</b>		<b>Signature</b>	

**SECOND-LEVEL APPROVAL COMMITTEE: Enter name of committee/group**

If the committee/group is happy to approve this document would the chair please sign below and send the document and the minutes from the approval committee to the author. To aid distribution all documentation should be sent electronically wherever possible.

<b>Name</b>		<b>Date</b>	Enter date
<b>Signature</b>			

## NOTES FOR AUTHORS


Please refer to the *Governance Standardisation Guideline* for detailed information.

### Document formatting

The main body of this template is in a table format to ensure consistency.

- **To add another row:**

Hover the cursor below the last row in the table. Select the addition symbol:



- **Text and style format:**

All main body text must be Arial 12pt Regular with left alignment. Headings should be Arial 14pt Bold and shaded blue. Sub headings must be Arial 12pt Bold:

1. MAIN HEADING – Arial 14pt Bold	
1.1	<b>Subheading – Arial 12pt Bold</b> Main body – Arial 12pt Regular
1.2	

- **Headers and footers:**

These should be as on this document.

The front cover page has a header but no footer.

All other pages have the following:

No header.

Footer: Policy Title, version number and date (YY) to the left hand side.

Page number in the format “Page n of nn” to the right. This will start at page two on the “Document Version Control Schedule” page. Page one being the front cover sheet.


In the centre of the footer in red type will be the message:

*CAUTION: Refer to the Document Library for the most recent version of this document  
Uncontrolled copy when printed*

To amend the footer; double left-click anywhere within the Footer section. Once complete, double click anywhere within the main body of the page in order to close the Footer.

- **Additional pages:**

To create a new page within the document, first set your cursor directly above the point of which you would like the new page to start. Select *Insert* from the main tab section, followed by *Blank Page*:



- **Appendices:**

It is not mandatory to include appendices in the table format. Appendices can be added to the end of this document.

## References

**All Rights Reserved. The East of England Neonatal ODN withholds all rights to the maximum extent allowable under law. Any unauthorised broadcasting, public performance, copying or re-recording will constitute infringement of copyright. Any reproduction must be authorised and consulted with by the holding organisation (East of England Neonatal ODN).**

**The organisation is open to share the document for supporting or reference purposes but appropriate authorisation and discussion must take place to ensure any clinical risk is mitigated. The document must not incur alteration that may pose patients at potential risk. The East of England Neonatal ODN accepts no legal responsibility against any unlawful reproduction. The document only applies to the East of England region with due process followed in agreeing the content.**

## EXCEPTIONAL CIRCUMSTANCES FORM

Form to be completed in the **exceptional** circumstances that the Trust is not able to follow ODN approved guidelines

Details of person completing the form:	
Title:	Organisation:
First name:	Email contact address:
Surname:	Telephone contact number:
Title of document to be excepted from:	
Rationale why Trust is unable to adhere to the document:	
Signature of speciality Clinical Lead:	Signature of Trust Nursing / Medical Director:
Date:	Date:
Hard Copy Received by ODN (date and sign):	Date acknowledgement receipt sent out:

Please email form to: [mandybaker6@nhs.net](mailto:mandybaker6@nhs.net) requesting receipt.

Send hard signed copy to: Mandy Baker  
 EOE ODN Executive Administrator  
 Box 93  
 Cambridge University Hospital  
 Hills Road  
 Cambridge CB2 0QQ